Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr:30 Suppl 3:39-44.
doi: 10.1111/hae.14976. Epub 2024 Mar 13.

Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies

Maria Elisa Mancuso  1   2 , Stacy E Croteau  3 , Robert Klamroth  4   5
Affiliations
Review

Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies

Maria Elisa Mancuso et al. Haemophilia. 2024 Apr.

Abstract

Introduction: Over the last decades progress in haemophilia treatment has been remarkable and prophylaxis with clotting factor concentrates in haemophilia A and B has been established as the standard of care in individuals with haemophilia and a severe bleeding phenotype. Besides clotting factor products with prolonged half-life non-factor therapies were developed which enable prophylaxis via subcutaneous administration. Factor VIIIa mimetics like emicizumab facilitate the coagulation pathway and are used in routine clinical practice for indivdiduals with haemophilia A. Rebalancing therapeutic agents like fitusiran, concizumab, marstacimab and serpin PC block the anticoagulant pathway and clinical trials using these products in individuals with haemophilia A and B are ongoing.

Aim and methods: A narrative review to asess the benefits and risks of non-factor therapies taking in to account re-defined haemophilia treatment goals.

Results: Prophylaxis for prevention of bleeds using non-factor products by subcutaneous administration is effective and results in reductions of bleeding episodes in individuals with haemophilia A or B with and without inhibitors. The treatment with emicizumab showed tolerable safety both in clinical trials and long-term real-world observations with few thrombotic events. In some clinical trials with rebalancing therapies (fitusiran and concizumab) thrombotic events occurred. Monitoring of the haemostatic function of novel therapies especially with concomitant haemostatic treatment is not yet established.

Conclusion: With the advent of novel therapeutic agents including factor concentrates with ultra-long half-life and improved FVIIIa mimetics aimed at raising the bar of protection into the non-hemophilic range redefinition of haemophilia treatment goals is eagerly needed.

Keywords: emicizumab; factor VIII mimetics; haemophilia; prophylaxis; rebalancing agents.

PubMed Disclaimer

References

REFERENCES

    1. Srivastava A, Santagostino E, Dougall A, et al, WFH Guidelines for the Management of Hemophilia panelists and co‐authors. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(6):1‐158.
    1. Hermans C, Noone D, Benson G, et al. Hemophilia treatment in 2021: choosing the “optimal” treatment using an integrative, patient‐oriented approach to shared decision‐making between patients and clinicians. Blood Rev. 2022;52:100890.
    1. Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half‐life clotting factor concentrates to gene editing. Lancet. 2021;397(10274):630‐640.
    1. Young G, Liesner R, Chang T, et al. A multicenter, open‐label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127‐2138.
    1. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809‐818.

LinkOut - more resources